Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Pieter Paassen"'
Autor:
Michiel T.H.M. Henkens, Jerremy Weerts, Job A.J. Verdonschot, Anne G. Raafs, Sophia Stroeks, Maurits A. Sikking, Hesam Amin, Sanne G.J. Mourmans, Chrit B.G. Geraeds, Sandra Sanders‐van Wijk, Arantxa Barandiarán Aizpurua, Nicole H.M.K. Uszko‐Lencer, Ingrid P.C. Krapels, Petra F.G. Wolffs, Han G. Brunner, Rick E.W. Leeuwen, Wouter Verhesen, Simon M. Schalla, Antonius W.M. Stipdonk, Christian Knackstedt, Xiaofei Li, Myrurgia A. Abdul Hamid, Pieter Paassen, Mark R. Hazebroek, Kevin Vernooy, Hans‐Peter Brunner‐La Rocca, Vanessa P.M. Empel, Stephane R.B. Heymans
Publikováno v:
Esc heart failure, 9(2), 1463-1470. John Wiley & Sons Inc.
AIMS: Heart failure (HF) represents a clinical syndrome resulting from different aetiologies and degrees of heart diseases. Among these, a key role is played by primary heart muscle disease (cardiomyopathies), which are the combination of multifactor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81a9420ceb760c74618efaf2af27d4ba
https://doi.org/10.1002/ehf2.13833
https://doi.org/10.1002/ehf2.13833
Autor:
Alexander P. J. Vlaar, Endry H. T. Lim, Sanne Bruin, Simon Rückinger, Korinna Pilz, Matthijs C. Brouwer, Ren‐Feng Guo, Leo M. A. Heunks, Matthias H. Busch, Pieter Paassen, Niels C. Riedemann, Diederik Beek
Publikováno v:
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 15(4), 854-858. Wiley-Blackwell
Clinical and Translational Science, 15(4), 854-858. Wiley
Clinical and Translational Science, 15(4), 854-858. Wiley
Recently, we reported the phase II portion of the adaptive phase II/III PANAMO trial exploring potential benefit and safety of selectively blocking C5a with the monoclonal antibody vilobelimab (IFX-1) in patients with severe coronavirus disease 2019
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feeb71e1474d6bf1ea240bac3c50a9d2
https://pure.amc.nl/en/publications/the-antic5a-antibody-vilobelimab-efficiently-inhibits-c5a-in-patients-with-severe-covid19(141782fd-9783-4a6e-bcf1-3bf4e39fd488).html
https://pure.amc.nl/en/publications/the-antic5a-antibody-vilobelimab-efficiently-inhibits-c5a-in-patients-with-severe-covid19(141782fd-9783-4a6e-bcf1-3bf4e39fd488).html
